Nuclear expression of Y-box binding protein-1 (YB-1) is closely associated not only with global drug resistance and expression of several growth factor receptors in various human malignancies but also with overall patient survival. Methods: The effect of YB-1 knockdown on expression of epidermal growth factor receptor (EGFR) family proteins was examined by Western blot using human lung cancer cell lines. Immunohistochemistry was used to evaluate the expression of nuclear YB-1 and EGFR family proteins in patients with non-small cell lung cancer (NSCLC) (n ϭ 104). Results: In the five NSCLC cell lines, expressions of EGFR, human epidermal growth factor receptor 2 (HER2), HER3, and hepatocyte growth factor receptor (c-Met) in PC-9 cells; of HER2 and c-Met in EBC-1 cells; and of HER3 in QG56 cells were down-regulated by YB-1 knockdown. By immunohistochemical analysis, we observed that HER3 expression was significantly negatively correlated with nuclear YB-1 expression in squamous cell carcinoma (p ϭ 0.038). HER2 expression was positively correlated with nuclear YB-1 expression in adenocarcinoma (p ϭ 0.052). Nuclear expression of YB-1 correlated with overall survival of all patients (p ϭ 0.028) and of patients with adenocarcinoma (p ϭ 0.007). Furthermore, there was a significant difference in therapeutic efficacies of gefitinib between patients with nuclear YB-1 expression and those with non-nuclear YB-1 expression in patients with NSCLC (p ϭ 0.004,
T he Y-box binding protein-1 (YB-1), whose cold shock domain is highly conserved, plays essential roles in DNA damage repair and in both transcriptional and translational regulation of various genes in nucleus and cytoplasm. 1, 2 In the nucleus, YB-1 recognizes DNA damage induced by cisplatin and radiation and promotes transcription of drugresistance relevant genes such as MDR1/ABCB1, a representative multidrug resistance-related ATP-binding cassette transporter, and major vault protein/lung resistance-related protein, a drug-resistance-related vault protein, suggesting the applicability of YB-1 as a global biomarker of drug resistance. 2, 3 Moreover, nuclear expression of YB-1 significantly correlates with the survival of patients with various malignancies, including ovarian cancer, 4, 5 synovial sarcoma and rhabdomyosarcoma, 6, 7 lung cancer, 8 breast cancer, 9 and pediatric glioblastoma. 10 Most of these patients show a close association of nuclear YB-1 expression with poor prognosis, irrespective of treatment modality. It is likely that multiple tumor characteristics, including growth and metastasis/invasion as well as acquisition of global drug resistance, cause YB-1 expression to be associated with poor prognosis in cancer patients.
Nuclear expression of YB-1 is promoted through PI3K/ Akt signaling in human breast and ovarian cancer cells in response to growth stimulation, 11, 12 and YB-1 knockdown suppresses expression of DNA replication-related and growth/cell cycle-related genes as well as growth factor genes. 12, 13 YB-1 gene knock-in promotes development of breast cancer of various histologic types in animal models, suggesting that YB-1 is a breast cancer oncogene. 14 YB-1 knockdown in mice causes embryonic lethality and severe growth retardation. 15, 16 Furthermore, YB-1 overexpression induces epidermal growth factor (EGF)-independent growth through constitutive EGF receptor (EGFR) activation in human mammary cells in vitro. 17 Wu et al. 18 reported that the introduction of an Akt-activation-insensitive mutation into YB-1 caused a marked decrease in the expression of both EGFR and human epidermal growth factor receptor 2 (HER2), suggesting a close linkage between YB-1 and expression of EGFR and HER2 in breast cancer cells in vitro. YB-1 knockdown also results in markedly decreased expression of EGFR and HER2 in some human breast cancer cell lines in culture. 9 Taken together, these basic studies in vitro and in vivo strongly suggest that YB-1 is closely involved in EGF/transforming growth factor-␣-dependent and -independent tumor growth and carcinogenesis in cancer.
The clinical study by Janz et al. 19 was the first to demonstrate the close association of nuclear YB-1 expression with HER2 expression in primary breast cancers. This correlation with the expression of EGFR and HER2 in patients with breast cancer (n ϭ 389) was further supported by array studies with tumor tissue. 18 Of various genes, including EGFR, HER2, ER␣, ER␤, and CXCR4, that could be affected by YB-1 knockdown in vitro, biostatistical analysis showed that YB-1 nuclear expression was positively associated with the expression of HER2 and negatively associated with the expression of CXCR4 and ER␣. 9 A recent study by Stratford et al. 20 also showed the possible involvement of YB-1 in the therapeutic efficacy of an EGFR-targeting drug, gefitinib, in basal-like breast cancer. These findings suggest that YB-1 may play a key role in the expression of cell growth-related genes, including EGFR family genes, in breast cancer cells and may also modulate the therapeutic efficacy of EGFR family targeting drugs.
In this study, we determined the relationship between YB-1 expression and that of several growth factor receptors, EGFR, HER2, HER3, hepatocyte growth factor receptor (c-Met), and insulin-like growth factor 1 receptor (IGF-1R), in human lung cancer cell lines in culture. Moreover, we determined whether nuclear YB-1 expression was correlated with the expression of EGFR, HER2, HER3, c-Met, and phosho Akt (pAkt) in tumor tissue from patients with non-small cell lung cancer (NSCLC), and also whether therapeutic efficacy of gefitinib was correlated with nuclear YB-1 expression. We discuss the clinical and immunohistochemical characteristics of NSCLC with particular reference to the absence or presence of nuclear YB-1 expression and the expression of EGFR family proteins.
MATERIALS AND METHODS

Cell Lines and Reagents
PC-9, QG56, and 11_18 were cultured in Roswell Park Memorial Institute (culture medium) supplemented with 10% fetal bovine serum. A549 and EBC-1 were cultured in Dulbecco's minimum essential medium supplemented with 10% fetal bovine serum. Anti-YB-1 was generated as described previously. 21 Anti-EGFR, IGF-1R, Akt, pAkt, Erk, and pErk antibodies were obtained from Cell Signaling Technology (Beverly, MA). Anti-HER2 was purchased from Upstate, Inc. (Lake Placid, NY). Antic-Met and anti-HER3 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-GAPDH was purchased from TREVIGEN (Gaithersburg, MD).
Small Interfering RNA Transfection and Immunoblotting
The small interfering RNA (siRNA) corresponding to the nucleotide sequence of YB-1 was purchased from QIAGEN. 9 SiRNA duplexes were transfected with Lipofectamine RNAiMAX and Opti-MEM medium (Invitrogen, Carlsbad, CA) according to the manufacturer's recommendations. Forty-eight hours after siRNA transfection, cells were lysed in cold protein extraction reagent (M-PER; PIERCE, Rockford, IL) with protease inhibitors and phosphatase inhibitors. Nuclear and cytoplasmic fractions were prepared as described previously. 12 Lysates were subjected to SDS-PAGE and blotted onto Immobilon membrane (Millipore Corp., Bedford, MA). After transfer, the membrane was incubated with the primary antibody and visualized with secondary antibody coupled to horseradish peroxidase and enhanced chemiluminescence Western Blotting Detection Reagents (GE Healthcare, Piscataway, NJ). For cell proliferation assay, 2.5 ϫ 10 4 cells were seeded in 24-well plates (IWAKI, Tokyo, Japan) and cell number in each well was counted at 96 hours after transfection of siRNA.
Patients and Tumor Samples
We examined 104 patients with primary NSCLC whose tumors had been completely surgically removed in the Department of Surgery of Kurume University between 1997 and 2004. Among the 104 patients, 66 patients were diagnosed histologically as having adenocarcinoma and the other 38 patients were diagnosed as having squamous cell carcinoma. The age of the patients with NSCLC ranged from 41 to 82 years (median, 66 years). Of the total number of patients, 67 were men and 37 were women. The median follow-up was 1511.5 days with a range of 159 to 3801 days. Of these patients, 26 patients received gefitinib against recurrent disease after surgical resection between June 2003 and September 2008 with the median interval between operation and gefitinib treatment of 760 days (range, 225-3062 days). Five patients were treated with gefitinib as an initial therapy and the others were treated with gefitinib as a second-or a third-line therapy (21 patients, platinum doublets as first line; five patients, monotherapy, nonplatinum doublets, and platinum doublets as second line).
Immunohistochemistry
Paraffin-embedded tissue samples were cut at 4 m, placed on coated glass slides, and labeled with the following antibodies by the BenchMark XT (Ventana Automated Systems, Inc., Tucson, AZ) or ChemMate ENVISION (DakoCytomation, Glostrup, Denmark) methods: YB-1, EGFR, HER2, HER3, pAkt, and c-Met. The BenchMark XT method was used for YB-1, EGFR, HER2, and HER3. This automated system used the streptavidin biotin complex method with DAB as chromogen (Ventana iVIEW DAB Detection Kit). Antigen retrieval of YB-1 and HER2 was performed by heat treatment in CC1 (Ventana, Inc.) and that of EGFR and HER3 was performed by protease treatment (protease K, Ventana, Inc.). The ChemMate ENVISION method was used for pAkt and c-Met. Endogenous peroxidase activity was inhibited by incubating the slides in 3% H 2 O 2 for 5 minutes. Each slide was incubated overnight with the antibody at 4°C. For staining detection, DAB was used as chromogen. The samples were viewed using an Olympus BX51 microscope (Olympus, Tokyo, Japan).
Expression of YB-1 protein with variable intensity showed in the nuclei and/or cytoplasm with variable intensity. Only nuclei of cancer cells with strong expression were interpreted as positive. Expression of EGFR and HER2 was classified into four categories: score 0, no staining at all or weak membrane expression in Ͻ10% of cancer cells; score 1ϩ, weak expression in Ͼ10% of cancer cells; score 2ϩ, weak to moderate expression on the entire membrane in Ͼ10% of the cancer cells; and score 3ϩ, strong expression on the entire membrane in Ͼ10% of cancer cells. HER3, pAkt, and c-Met were classified into the same four categories but the localization of expression included both membrane and cytoplasm. The scoring of immunohistochemistry (IHC) was defined as follows in order that the difference in the number of patients in two categories of negative and positive were as small as possible. The expressions of HER2 and pAkt were defined as follows: scores of 2ϩ or 3ϩ were regarded as positive and scores of 0 or 1were regarded as negative. The expression of IHC for EGFR, HER3, and c-Met was defined as follows: score of 3ϩ was regarded as positive and scores of 0, 1, or 2ϩ were regarded as negative. All IHC studies were evaluated by two IHC-experienced reviewers (A.K. and M.K.) who were blinded to the clinical status of the patients.
Statistical Analysis
Associations between histologic type and clinicopathologic findings (age, gender, smoking status, stage, and histologic differentiation) and molecular markers (EGFR, HER2, HER3, c-Met, and pAkt) were tested by Fisher's exact test. Associations between YB-1 and clinicopathologic findings and other molecular markers were tested in similar ways. A p value Ͻ0.05 was regarded as statistically significant unless indicated. The overall survival was defined as time to death because of any case from the date of surgical operation. The relationships between overall survival and YB-1 expression, and other clinicopathologic findings and molecular markers, were examined by the Kaplan-Meier method and the log-rank test. Hazard ratios (HRs) were estimated by Cox regressions. Adjusted HRs for possible confounding factors were also estimated by applying the Cox regression models with the factors as explanatory variables. Twenty-six patients were treated with gefitinib after progressive disease. Time to further progressive disease from initiation of gefitinib treatment was evaluated for these patients. The effect of YB-1 on the further progressive disease in the presence of gefitinib was examined in an exploratory matter by the Kaplan-Meier method and the log-rank test. Statistical analysis was performed with SAS version 9.1 (SAS Institute, Inc., Cary, NC) and revised version 2.7.0.
RESULTS
Knockdown of YB-1 and Expression of the EGFR, HER2, HER3, and c-Met Genes in NSCLC Cell Lines
We examined expression of the growth factor receptors EGFR, HER2, HER3, c-Met, and IGF-1R in five NSCLC cell lines. Expression of YB-1 was observed in both total cell fraction and nucleus in all the five NSCLC cell lines, although expression of YB-1 in both fractions of PC-9 and EBC-1 cells was only about 20% or less than that in the other three lines (Figures 1A, B) . Expression levels of EGFR, and EBC-1. Of the five lines, expression of growth factor receptors was particularly susceptible to siRNA-dependent down-regulation in PC-9 and EBC-1 cells, which contain relatively lower levels of YB-1. However, we did not observe decreased expression of growth factor receptor proteins by YB-1 knockdown in 11_18 and A549 cells (Figures 2A, B) . Overall, the reduced expression of EGFR family proteins and c-Met protein by YB-1 knockdown in some NSCLC cell lines suggests an association between YB-1 levels and expression of EGFR family proteins or c-Met protein. In addition, proliferation of Figure 2C ).
Association of Nuclear YB-1 Expression with Expression of EGFR, HER2, HER3, c-Met, and pAkt in NSCLC
To examine which genes are specifically associated with nuclear YB-1 localization in human NSCLC, we selected five molecular markers: EGFR, HER2, HER3, c-Met, and pAkt. Representative immunohistochemical staining patterns are shown in Figure 3 . Expression of nuclear YB-1 was detected in 44 of 104 patients. Table 1 shows the results of Fisher's exact test for association between YB-1 and each of the molecular markers in adenocarcinoma and squamous cell carcinoma. To avoid misinterpretations arising from Simpson's paradox, 22 we emphasis on analysis by histologic differentiation. Such analysis demonstrated that there was significant negative correlation between nuclear expression of YB-1 and expression of HER3 in patients with squamous cell carcinoma (p ϭ 0.038). There was also a trend to a correlation between nuclear expression of YB-1 and expression of HER2 in patients with adenocarcinoma (p ϭ 0.052).
Nuclear YB-1 Expression and Survival of Patients with NSCLC
The estimated product-limit survival functions of nuclear YB-1 are shown in Figure 4 , and the results of log-rank tests and unadjusted HRs are given in Table 2 . Survival curves for patients with positive nuclear YB-1 expression were significantly different from those with negative expression (HR ϭ 1.73; 95% confidence interval [CI] 1.05-2.83; p ϭ 0.028). Further analysis showed that positive nuclear YB-1 expression significantly affected survival in adenocarcinoma (HR ϭ 2.40; 95% CI 1.25-4.58; p ϭ 0.007) but not in squamous cell carcinoma (HR ϭ 1.50; 95% CI 0.60 -3.72; p ϭ 0.381; Table 2) .
Adjusted HRs for patients with positive nuclear YB-1 expression relative to those with negative nuclear YB-1 expression were obtained by applying the Cox regression models with sex, smoking status, and histologic type as explanatory variables (Table 3) . Stage was not adjusted in the Cox regression model, because it might be an intermediate variable between YB-1 expression and overall survival. 23 The adjusted HR was statistically significantly different from unity (HR ϭ 1.96; 95% CI 1.13-3.38; p ϭ 0.016) indicating that nuclear YB-1 expression affects overall survival even after adjusting for possible confounding factors. The Cox regression models with sex and smoking status were also applied separately by histologic type to determine the interaction between nuclear YB-1 and histologic type. Adjusted HRs for YB-1 expression were similar between adenocarcinoma and squamous cell carcinoma, although they were statistically significant only for patients with adenocarcinoma (HR ϭ 2.19; 95% CI 1.12-4.28; p ϭ 0.022 for adenocarcinoma, and HR ϭ 2.14; 95% CI 0.74 -6.15; p ϭ 0.158 for squamous cell carcinoma).
Nuclear YB-1 Expression and Therapeutic Efficacy of Gefitinib
Twenty-six patients administrated gefitinib after progressive disease. Among 26 patients, 24 patients were histologically diagnosed adenocarcinoma and other two patients were diagnosed squamous cell carcinoma. Eight of them were men and 18 were women. Seven of them were smoker and 19 were nonsmoker. The estimated product-limit survival functions of nuclear YB-1 for time to further disease progression from the initiation of gefitinib treatment are shown in Figure  5 . Although patients' number for gefitinib treatment was limited, the survival curves for patients with positive nuclear YB-1 expression and those with negative expression are quite distinct with statistical significance (p ϭ 0.004).
DISCUSSION
Wu et al. 18 used array studies to establish a close correlation between total YB-1 expression and EGFR and HER2 expression in tumor tissue from patients with breast cancer. Our recent immunohistochemical analysis demonstrated that nuclear YB-1 expression is positively correlated with HER2, and negatively correlated with ER␣ and CXCR4, but not with EGFR in breast cancer clinical specimens. 9 In this study, YB-1 knockdown in five NSCLC cell lines caused down-regulation of EGFR, HER2, HER3, and c-Met in PC-9; of HER3 and c-Met in EBC-1; and of HER3 in QG56. There was no change in expression of growth factor receptor family proteins in the other two cell lines. However, cell proliferation was markedly suppressed by YB-1 knockdown in all five cell lines suggesting that YB-1 siRNA-induced inhibition of cell proliferation might not involve attenuation of these growth factor receptors. The underlying mechanism of YB-1 siRNA-induced growth inhibition in these cell lines remains unknown. Immunohistochemical analysis of clinical samples of NSCLC showed that nuclear YB-1 expression was negatively correlated with HER3 expression in squamous cell carcinoma (p ϭ 0.038) and positively correlated with HER2 expression in adenocarcinoma (p ϭ 0.052). However, nuclear YB-1 expression was not significantly correlated with EGFR or c-Met expression in either squamous cell carcinoma or adenocarcinoma.
Overexpression of HER2 in an NSCLC cell line with very low EGFR and high HER3 expression levels sensitizes these cells to growth inhibition by the EGFR-targeting drug gefitinib, and gefitinib abrogated formation of HER2/HER3 heterodimers. 24 Consistent with this report, there is a strong correlation between HER3 expression and sensitivity to gefitinib. 25 Another EGFR-targeting drug, erlotinib, also inhibits HER2 tyrosine kinase, and HER2/HER3 heterodimer formation sensitizes lung cancer cells to growth inhibition by erlotinib. 26 Taken together, expression of HER2 and HER3 coupled with formation of their heterodimers plays a critical role in determining the therapeutic efficacy of the EGFRtargeting drugs gefitinib and erlotinib. 27, 28 The possible link between nuclear YB-1 expression and HER2 expression in adenocarcinoma (p ϭ 0.052) might be in part responsible for the correlation between nuclear YB-1 expression and survival of patients with adenocarcinoma NSCLC. Nuclear YB-1 expression is positively correlated with HER2 expression in patients with breast cancer (p ϭ 0.015). 9 Thus, HER2 expression could be modulated by nuclear YB-1 expression not only in patients with breast cancer 9 but also in patients with adenocarcinoma NSCLC (this study). HER3 expression was inversely correlated with nuclear expression of YB-1 in squamous cell carcinoma (p ϭ 0.038), but HER3 expression alone did not correlate with survival of patients with NSCLC or of the subset with squamous cell carcinoma. It seems unlikely that the inverse correlation of nuclear YB-1 expression with HER3 expression is a factor in the poor prognosis associated with nuclear YB-1 expression in patients with squamous NSCLC.
In addition to the effect of altering the status of EGFR family proteins on the therapeutic efficacy of EGFR-targeting drugs, amplification of c-Met has been identified as another acquired drug resistance mechanism. 29 c-Met modifies drug sensitivity to gefitinib through HER3-dependent activation of the PI3K/Akt pathway. 25 Moreover, Cappuzzo et al. 30 reported that gefitinib-treated patients with a high-HER3 gene copy number had significantly higher response rates and times to progression, although with no improvement in overall survival. Nuclear expression of YB-1 also affected expression of c-Met in two NSCLC cell lines in culture, but we could not observe any significant correlation between nuclear YB-1 expression and c-Met expression in NSCLC. This suggests that it is unlikely that nuclear YB-1 expression determines c-Met expression in patients with NSCLC.
Nuclear YB-1 expression is often associated with poor prognosis in various human malignancies, including breast cancer. 4 -10 In NSCLC, our previous IHC study on 196 patients demonstrated that nuclear YB-1 expression is significantly associated with poor prognosis in all patients (p ϭ 0.0424) and in patients with squamous cell carcinoma (p ϭ 0.0313), but not in patients with adenocarcinoma (p ϭ 0.2015). 8 This study demonstrated a close association of nuclear YB-1 expression with poor prognosis in all patients (p ϭ 0.028) and in patients with adenocarcinoma (p ϭ 0.007), but not in patients with squamous cell carcinoma (p ϭ 0.381). This inconsistency may result from the small number of patients with squamous cell carcinoma in this study. The results of the Cox regression analysis given in Table 3 provide similar estimates of the HR of nuclear YB-1 expression in adenocarcinoma and squamous cell carcinoma, although they were not necessarily statistically significant. Further studies with more definitive clinicopathological characterization of the patients included are required to establish the types of NSCLC in which nuclear expression of YB-1 predicts poor prognosis.
Of patients with NSCLC (n ϭ 104) tested in this study, we examined whether therapeutic efficacies of gefitinib were associated with expression levels of nuclear YB-1 expression when recurrent 26 patients (24 adenocarcinoma and two squamous cell carcinoma) were treated with gefitinib. Although the number of treated patients was small, the absence or presence of nuclear YB-1 expression shows a significant correlation with differences in the survival curves after progression disease. Concerning EGFR mutations that are highly susceptible to the therapeutic efficacy of gefitinib, we also observed statistically significant differences between patients with mutant EGFR and those with wild-type EGFR (Azuma et al, unpublished data). Nuclear YB-1 expression might have a significant predictive value for progression disease in patients with NSCLC when treated with EGFR-targeting drug. Further study is in progress whether nuclear expression of YB-49 could be associated with gefitinib-susceptible EGFR mutations.
In conclusion, our results show that nuclear YB-1 expression is strongly associated with overall survival of patients with NSCLC (n ϭ 104). Of the EGFR family proteins, nuclear YB-1 expression is associated with expression of HER2 in both histologic types of NSCLC and of HER3 in squamous cell carcinoma type of NSCLC. Therefore, expression of YB-1 in the nucleus might affect the therapeutic efficacy of EGFR-targeting drugs. Nuclear YB-1 expression is associated with progressive disease survival of patients with NSCLC (n ϭ 26) when treated with gefitinib. Together, these observations indicate that nuclear YB-1 is a novel biomarker in NSCLC.
